Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $14.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target boosted by Citigroup from $12.00 to $14.00 in a research report released on Friday morning,Benzinga reports. Citigroup currently has a neutral rating on the stock.

Several other equities research analysts also recently issued reports on NTLA. Wedbush restated a “neutral” rating and set a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Oppenheimer reduced their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Chardan Capital lowered their price target on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research report on Friday. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Finally, Barclays decreased their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $42.12.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $10.09 on Friday. Intellia Therapeutics has a 1 year low of $8.96 and a 1 year high of $34.87. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80. The business has a fifty day simple moving average of $10.85 and a two-hundred day simple moving average of $15.59.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after acquiring an additional 794 shares during the last quarter. Capstone Investment Advisors LLC lifted its stake in Intellia Therapeutics by 1.4% in the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after buying an additional 831 shares during the period. KBC Group NV lifted its stake in Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares during the period. Axxcess Wealth Management LLC grew its position in shares of Intellia Therapeutics by 5.4% during the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock worth $415,000 after buying an additional 1,044 shares during the period. Finally, Ensign Peak Advisors Inc increased its stake in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after acquiring an additional 1,100 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.